Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Du,F. (2) Wang,L. (2) Wang,H.-X. (1) Wang,H.X. (1) Zhang,H.-M. (1) Zhang,H.M. (1) Zhang,W.J. (1) Mais... Palavra-chave Atypical chronic myeloid leukemia (1) CSF3R mutation (1) Chemotherapy (1) Chronic neutrophilic leukemia (1) Circulating endothelial progenitor cells (1) Multiple myeloma (1) SETBP1 mutation (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2015 (2) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature BJMBR Wang,L.; Du,F.; Zhang,H.-M.; Wang,H.-X.. We report the case of a father and son diagnosed with atypical chronic myeloid leukemia (aCML). Both patients harbored SETBP1 mutations, which are present in 24.3% of aCML patients. Moreover, both shared the variant encoding p.Pro737His, but the aCML severity was greater in the son because of the presence of two other missense mutations causing p.Asp868Asn and p.Ser885Arg alterations. SETBP1 mutations may be associated with an adverse prognosis, so their detection would help in the diagnosis of aCML and the determination of a patient's prognosis. Tipo: Info:eu-repo/semantics/article Palavras-chave: Atypical chronic myeloid leukemia; SETBP1 mutation; Chronic neutrophilic leukemia; CSF3R mutation. Ano: 2015 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000700583 Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone BJMBR Wang,L.; Du,F.; Zhang,H.M.; Zhang,W.J.; Wang,H.X.. Four cycles of chemotherapy are required to assess responses of multiple myeloma (MM) patients. We investigated whether circulating endothelial progenitor cells (cEPCs) could be a biomarker for predicting patient response in the first cycle of chemotherapy with bortezomib and dexamethasone, so patients might avoid ineffective and costly treatments and reduce exposure to unwanted side effects. We measured cEPCs and stromal cell-derived factor-1α (SDF-1α) in 46 MM patients in the first cycle of treatment with bortezomib and dexamethasone, and investigated clinical relevance based on patient response after four 21-day cycles. The mononuclear cell fraction was analyzed for cEPC by FACS analysis, and SDF-1α was analyzed by ELISA. The study population was... Tipo: Info:eu-repo/semantics/article Palavras-chave: Chemotherapy; Circulating endothelial progenitor cells; Multiple myeloma. Ano: 2015 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000800736 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco